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ABSTRACT 
 
Age-related muscle atrophy is a consequence of normal aging characterized by 
decreases in muscle mass and strength. The mechanism(s) underlying the loss of 
muscle mass with increasing age is not fully understood, however recent data has 
suggested that muscle cell apoptosis may be involved. Here we investigate how aging 
affects the regulation of muscle apoptosis in the extensor digitorum longus (EDL) and 
soleus muscles of young (6-month), aged (26-month), and very aged (30-month) female 
Fischer 344/NNiaHSD X Brown Norway / BiNia (F344BN) rats. EDL and soleus muscle 
mass/body weight ratios were lower in aged animals but not different between 26- and 
30-months of age. Decrease in muscle mass was associated with increased TdT-
mediated dUTP nick-end labeling (TUNEL) positive immunoreactivity in both EDL and 
soleus. With advancing age the time course and magnitude of changes in Bax, Bcl-2, 
caspase-3, caspase-9, caspase-12 and cleavage of α-fodrin protein were regulated 
differently between muscles. These data demonstrated that decreases in muscle mass, 
and increases in muscle cell apoptosis appear to be caspase independent and differ 
between fiber types in the female F344BN rats with aging.  
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CHAPTER 1 
 
Introduction 
 
Sarcopenia is the loss of muscle mass and strength due to the aging process [1-
3]. Sarcopenia contributes to physical disability, a loss of independence and increases 
the risk of injury in the elderly [4,5]. Age-associated muscle atrophy is emerging as a 
major health concern: during the 20th century, the number of persons in the United 
States under age 65 has tripled. According to the U.S. census bureau (1995) it is 
anticipated that the number of elderly will more than double between now and the year 
2050.  It has been estimated that the direct healthcare cost of sarcopenia in United 
States was $18.5 billion ($ 10.8 billion in men, $ 7.7 billion in women) in 2000, and this 
number is expected to increase [6].  
Sarcopenia occurs at an earlier age in women [7]. Why sex may affect the 
incidence of sarcopenia is not well understood. Recent data has demonstrated that 
apoptosis may play a considerable role in mediating the progression of muscle loss in 
both rats and humans [8,9]. Apoptosis is programmed cell death that is characterized by 
DNA fragmentation, nuclear condensation, proteolysis, membrane blebbing and cell 
fragmentation [10-12]. Age associated adaptations like disuse, denervation, deficient 
satellite cell recruitment, mitochondrial dysfunction, oxidative stress, and decline in 
anabolic hormones synthesis may be responsible for activation of muscle apoptosis [13-
17]. It has been postulated that mitochondria are centrally involved in activating 
apoptosis via caspase-dependent and independent mechanisms [18-20]. The 
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mitochondrial pathway of apoptosis can be initiated by reactive oxygen species [21], 
which can cause the  mitochondria to release cytochrome c into the cytosol and 
formation of the apoptosome. Once the apoptosome is formed, procaspase-9 can 
undergo auto cleavage into an activate caspase-9 [22,23]. Caspase-9 then cleaves and 
activates procaspase-3. Active caspase-3 subsequently cleaves a wide range of protein 
substrates resulting in characteristic morphological changes in the nucleus, DNA 
fragmentation and cytoskeletal reorganization [24]. This caspase cascade activation 
results in disintegration of cell into apoptotic bodies. Recent data suggests that Bcl-2 
family members can either promote (e.g., Bax, Bak, Bid, Bad and Bim) or prevent (e.g., 
Bcl-2 and Bcl-XL) the release of cytochrome c from mitochondria [25]. In particular, 
levels of pro-apoptotic Bax and anti-apoptotic Bcl-2 and their ratio determines the fate of 
cytochrome c release [26]. In a caspase-independent manner, mitochondria can also 
release proapoptotic proteins, such as apoptosis inducing factor (AIF), Omi, and 
endonuclease G (endo G) [23]. Once in cytosol, these proteins translocate to the 
nucleus and induce apoptosis by DNA fragmentation. Alternatively, increased 
endoplasmic reticulum stress with aging can contribute to calcium dyshomeostasis 
[27,28] which can lead to the activation of procaspase-12 [29]. Recent data has 
demonstrated that caspase-independent apoptosis is responsible for sarcopenia in male 
F344BN rats [30]. In addition it has been shown that fast twitch and slow twitch muscles 
in male animals respond differently during aging [31]. Whether similar mechanisms and 
differences between muscle types are observed in the aging female F344BN rat has not 
been investigated.  
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Purpose 
Our long term goal is to elucidate intracellular signaling mechanisms responsible for 
age-associated muscle atrophy. The purpose of the present study was to determine 
how aging affects apoptotic associated signaling pathways in female F344BN rats and 
whether differences in apoptotic signaling exist between muscle types. These goals will 
be accomplished by following specific aims. 
 
Specific Aim # 1   
To determine if age-related muscle atrophy is associated with increased myocyte 
apoptosis in the extensor digitorum longus (EDL) and soleus muscles of female 
F344BN rats. 
 
Hypothesis:   
Age-associated muscle atrophy will be associated with apoptosis in the EDL and soleus 
muscles of female F344BN rats. 
 
Specific Aim # 2   
To determine if the expression of muscle apoptosis regulators Bax and Bcl-2 is altered 
with aging in the EDL and soleus muscles of female F344BN rats. 
 
Hypothesis:   
Age-associated muscle atrophy will be associated with alterations in the expression of 
Bax and Bcl-2 in the EDL and soleus muscles of female F344BN rats. 
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Specific Aim # 3   
To determine if the expression of caspase-3, caspase-9 and caspase-12 is altered with 
aging in the EDL and soleus muscles of female F344BN rats. 
 
Hypothesis:   
Aging will be associated with alterations in the amount of caspase-3, caspase-9, and 
caspase-12 in the EDL and soleus muscles of female F344BN rats. 
 
Significance of study: 
Sarcopenia is associated with increased health care costs and negatively 
impacts quality of life for many of the United States aging population. According to 1995 
US census, the number of elderly women outnumbered elderly men by a ratio of 3 to 2. 
Sarcopenia is also a greater public health problem for women since they live longer and 
have higher rates of disability. This study will determine how aging alters the regulation 
of proteins thought to govern muscle apoptosis in females. This study will increase our 
understanding of the basic cellular mechanism underlying sarcopenia and be of 
potential use for the development of novel pharmacological and nutritional interventions 
to reverse or prevent sarcopenia.  
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CHAPTER 2 
Review of Literature 
Introduction:   
A review of the pertinent literature concerning the present study will be presented 
in the following chapter. The following areas will be addressed: 1. Effect of aging and 
gender on skeletal muscle mass and strength and 2. Molecular mechanisms of age-
related muscle atrophy. 
 
Effect of aging and gender on skeletal muscle mass and strength 
Older people experience difficulty in performing daily living activities due to a 
decline in the force-generating capacity of their skeletal muscles [32]. To evaluate this 
age-associated muscle loss several researchers have examined the cross sections of 
various limb muscles by measuring the whole muscle cross sections from cadaveric 
specimens or by using imaging techniques such as ultrasound, computer tomography or 
magnetic resonance imaging. Young et al.,1985 using ultrasonic imaging, reported 
reductions in the cross-sectional areas (CSA) of the quadriceps muscles in older men 
(25% less) and women (33% less) compared to young controls [33,34]. Computerized 
tomographic scanning showed similar reductions in the CSA of thigh (12.5%), all thigh 
muscles (14.7%), quadriceps femoris muscle (16.1%) , and flexor muscles (14.9%) in 
men [35]. Rice et al., 1989 reported decrease in elderly limb muscles size is associated 
with increase in non-muscle tissue (fat and connective tissue) [36]. It has been reported 
that men (14.8%) exhibited larger age-related decreases in total appendicular skeletal 
muscle mass than women (10.8%) [37]. Janssen et al. observed similar gender 
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differences by measuring skeletal muscle mass in a sample of 268 men and 200 
women between 18 and 88 years of age using whole body magnetic resonance imaging 
[38]. This age-related muscle atrophy  is due to reduction of fiber size, and reductions in 
fiber number with a preferential loss of  type II fibers  [39]. Thomas et al., 1985 studied 
the age-associated changes in fiber number and fiber type composition in EDL and 
soleus and diaphragm muscles of male F344BN rats using histochemical myosin 
ATPase fiber typing [40]. His data suggested that age-related losses in the number of 
muscle fibers and the preferential loss of type II (a and b) fibers may not be universally 
applicable. Jan Lexell et al., (1987), evaluated cross-sections of vastus lateralis muscles 
from 43 physically healthy men between 15 and 83 years of age, and suggested that 
sarcopenia begins around 25 years of age before accelerating thereafter [41]. This work 
also suggested that muscle atrophy is caused by a loss of fibers, with no predominant 
effect on any fiber type, and that it is accompanied by a reduction in fiber size, mostly of 
type II fibers. Although many studies have reported age-related muscle loss the 
mechanisms responsible for these changes have not been completely investigated.  
Aging studies using humans are complicated by ethical issues and by the fact 
that human aging occurs over many decades. Because of this a great deal of research 
on aging has been performed on the aged rats because of its small size, limited life 
span and cost. The Fisher 344/NNiaHSd X Brown Norway/BiNia (F344BN) rat model 
has been recommended by the National Institue of Aging (NIA) for aging studies given 
that it exhibits fewer age-related pathologies (e.g., glomerulonephritis, retinal atrophy, 
and leukemia) than other inbred strains [42]. Rice et al., 2005 reported that the F344BN 
provides a better model of the alterations seen in aging human muscle than the 
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F344/NNiaHSd rat model [43]. Pistilli et al., 2006 used fast plantaris of male F344BN 
rats to study molecular regulation of apoptosis in aging and muscle unloading models 
[44]. Lushj et al., 2008 suggested that this rat model show age dependent decline in 
muscle mass and fiber and an increase in fiber atrophy and nonmuscle tissue after 
analyzing the three of quadriceps muscle (vastus lateralis, rectus femoris, and vastus 
medialis) at different ages [45]. 
 
Summary:  
The age associated deterioration in size, mass, and strength of skeletal muscle 
that has been observed in human skeletal muscle can affect the quality of life. These 
age-associated changes in skeletal muscle may differ with gender and fiber type. The 
molecular mechanisms underlying the sarcopenia are not well understood.  
 
Molecular mechanisms responsible for age-related muscle atrophy 
The molecular mechanism(s) underlying sarcopenia are only poorly understood. 
It has been suggested that changes in proteolytic activity, neurologic deficits (loss of α-
motor neurons), hormonal alterations (decline in growth hormone, Insulin like growth 
factor-1, testosterone or estrogen) and degree of physical inactivity likely contribute to 
loss of skeletal mass and contractile function with aging [46,47]. Recent data has 
suggested that an increased incidence of apoptosis might represent a key mechanism 
driving the onset and progression of muscle loss [8,23]. It has been demonstrated that 
reductions in myonuclear number per fiber and increased incidence of DNA 
fragmentation (as assessed by TUNEL staining) are associated with muscle atrophy 
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caused by immobilization and denervation [48,49]. Although apoptosis may occur via 
several mechanisms, the mitochondria are thought to play a major regulatory role [18-
20]. Yasuhara et al., 2000 reported the role of mitochondria and caspase mediated 
mechanisms in muscle weight loss using burn injury model. This study suggests that 
increases in mitochondrial outer membrane permeabiliability leads to release of 
cytochrome c into the cytosol which activates caspase-3 [50]. After release of 
cytochrome c from the mitochondria, an apoptosis-initiating complex, the “apoptosome”, 
is assembled which consist of apoptotic protease activating factor-1 (Apaf-1), 
procaspase-9 and dATP. The apoptosome, when activated,  results in cleavage and 
activation of procaspase-9 [22,23]. Following the activation of caspase-9, caspase-3 
becomes activated which in turn leads to DNA fragmentation [24,47]. Reorganization of 
the cytoskeleton occurs concomitantly and results in disintegration of the cell into 
apoptotic bodies, eventually destroying the cell.  
Tews et al., 1997 reported that denervated muscle contained a greater number of 
apoptotic myonuclei and an increased BAX to Bcl-2 ratio compared to innervated 
muscle [51]. This shift of BAX/Bcl-2 ratio towards apoptosis may be one determining 
factor in influencing the cytochrome c release [24]. In addition, caspase-independent 
apoptosis has been shown to occur via release of apoptosis inducing factor (AIF), 
endonuclease G (endo G) from the mitochondria [8,52]. Once released in to cytosol 
they translocate to the nucleus and cleaves the chromatin DNA in to nucleosomal 
fragments independently of caspases.   Endoplasmic reticulum stress could also partly 
contribute to apoptosis by releasing the calcium into the cytosol [29] This leads to 
activation of caspase cascade by activated caspase-12.  Nonetheless, the specific 
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molecular mechanisms underlying the progression of muscle atrophy with aging remain 
to be determined. Strasser et al., 2000 observed that the age-related loss of skeletal 
muscle cells in human rhabdosphincter muscle was associated with increased 
apoptosis [53].  Similarly, Dirks et al., 2001 reported an increase in the number of 
apoptotic cells in the skeletal muscle of aging male Fischer 344 rats [8]. Rice et al., 
2006 suggested that mitochondrial-dependent apoptosis pathways may not play a 
primary role in the loss of muscle nuclei in the aging male F344BN rat model. In addition 
they also provide evidence suggesting that both proteolytic and apoptotic regulatory 
events are different between fiber types with aging [31]. Lushaj et al., 2008 reported 
age-related changes in fiber number, muscle mass, CSA and nonmuscle tissue of 
vastus lateralis, rectus femoris and vastus medialis (three of quadriceps muscles) at 3-
month intervals in male F344BN rats [45]. Marzetti et al., 2008 reported that 
mitochondrial caspase-independent apoptotic pathway may play a more prominent role 
in skeletal muscle loss than caspase-dependent apoptotic pathway in skeletal muscles 
of male F344BN rats [30]. To date, no reports have examined if the mechanisms 
responsible for age-related sarcopenia differ across gender.  
 
Summary:  
The molecular mechanisms responsible for age-related alterations in skeletal 
muscle remain elusive. Caspase-independent apoptosis appear to play a role in 
mediating sarcopenia in male rats. Additional evidence also suggests that apoptotic 
mechanisms may differ across muscle fiber type. How aging affects the regulation of 
apoptotic signaling in female muscle has not been investigated.  
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CHAPTER 3 
 
Effects of aging on regulators of muscle apoptosis in the female F344BN rat  
 
 
(Note: chapter 3 has been formatted for publication purpose) 
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Abstract 
Age-related muscle atrophy is a consequence of normal aging characterized by 
decreases in muscle mass and strength. The mechanism(s) underlying the loss of 
muscle mass with increasing age is not fully understood, however recent data has 
suggested that muscle cell apoptosis may be involved. Here we investigate how aging 
affects the regulation of muscle apoptosis in the extensor digitorum longus (EDL) and 
soleus muscles of young (6-month), aged (26-month), and very aged (30-month) female 
Fischer 344/NNiaHSD X Brown Norway / BiNia (F344BN) rats. EDL and soleus muscle 
mass/body weight ratios were lower in aged animals but not different between 26- and 
30-months of age. Decrease in muscle mass was associated with increased TdT-
mediated dUTP nick-end labeling (TUNEL) positive immunoreactivity in both EDL and 
soleus. With advancing age the time course and magnitude of changes in Bax, Bcl-2, 
caspase-3, caspase-9, caspase-12 and cleavage of α-fodrin protein were regulated 
differently between muscles. These data demonstrated that decreases in muscle mass, 
and increases in muscle cell apoptosis appear to be caspase independent and differ 
between fiber types in the female F344BN rats with aging.  
 
Keywords:  Aging; Apoptosis; Bax; Bcl-2; F344BN; Female; Muscle; 
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Introduction 
Aging in humans is characterized by losses in muscle mass and strength that 
can impair the ability of the aged to perform every day activities.  This age-related 
muscle atrophy is  characterized by muscle fiber loss with the elderly exhibiting nearly a 
30-40% decrease in total fiber number between the second and eighth decade of life 
[54]. The degree of muscle atrophy with aging appears to be greater in men than in 
women [38,55,56]. Although not completely elucidated, recent data has demonstrated 
that apoptosis may play a considerable role in mediating the progression of muscle loss 
in both rats and humans [8,9]. The mechanism(s) regulating this process are not well 
understood. Similarly, whether differences in the regulation of signaling processes 
involved in controlling apoptosis may differ across gender or between muscle types has 
not been clarified.    
Muscle apoptosis has been shown to occur in both a caspase-dependent and  
independent manner [18]. Recent data using male rats has demonstrated that the 
caspase-independent apoptotic pathway may play a prominent role in skeletal muscle 
loss [30,31]. In addition, other data has demonstrated that age-related apoptotic 
signaling may differ between different muscle types [31]. Whether similar mechanisms 
operate in aging female muscle is not known.  
On the basis of findings from our laboratory [57,58] and others [59] indicating that 
the male Fischer 344/NNiaHSD X Brown Norway / BiNia (F344BN) rats exhibits a 
similar level of sarcopenia to that seen in aging humans we examined the time course 
and regulation of apoptotic signaling in the fast-twitch muscle extensor digitorum longus 
(EDL) and the slow-twitch soleus muscles of adult, aged, and very aged female F344BN 
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rats. Consistent with previous reports that have employed male animals [31], our 
findings demonstrate that the regulation of age-related apoptotic signaling may differ 
across muscle fiber type.  
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Material and methods 
 
Animals 
All procedures were performed in accordance with the Guide for the Care and 
Use of Laboratory Animals as approved by the Council of the American Physiological 
Society as well as the Animal Use Review Board of Marshall University.  Procedures 
were conducted in strict accordance with Public Health Service animal welfare policy. 
Fully mature adult (6-months; n=4), post-menopausal aged (26-months; n=4) and very 
aged (30-months; n=4) female F344BN rats were obtained from the National Institute of 
Aging.  Rats were housed two per cage in an AAALAC approved vivarium.  Housing 
conditions consisted of a 12:12 hour dark-light cycle and temperature was maintained at 
22 ± 2 °C.  Animals were provided food and water ad libitum.  Rats were allowed to 
recover from shipment for at least two weeks before experimentation and during this 
time the animals were carefully observed and weighed weekly.  None of the older 
animals exhibited signs of failure to thrive such as precipitous weight loss, disinterest in 
the environment, or unexpected gait alterations. 
 
Materials 
Primary antibodies against Bax [#2772], Bcl-2 [#2876], caspase-3 [#9662], 
caspase-9 [#9506], caspase-12 [#2202], α-fodrin [#2122], glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) [# 2118], HRP-linked anti-rabbit IgG [#7074] and NIH-3T3 
control cell extracts [#9203] were obtained from Cell Signaling Technology  (Beverely, 
MA).  The TUNEL (terminal deoxynucleotidyl transferase-mediated dUTP nick-end 
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labeling) assay kit was purchased from Roche Diagnostics Corporations (Indianapolis, 
IN).  Antibody against dystrophin (C-terminus) was from Novocastra Laboratories Ltd. 
(Newcastle, UK). Texas Red anti-mouse secondary antibody [#TI-2000] and mounting 
medium with DAPI [# H-1500] was acquired from Vector Laboratories, Inc. (Burlingame, 
CA).  Precast 10% and 15% SDS-PAGE gels were procured from Lonza (Rockland, 
ME) while the Enhanced Chemiluminescence (ECL) Western Blot Detection Reagents, 
Hyperfilm and Hybond nitrocellulose membranes were attained from Amersham 
Biosciences (Piscataway, NG).Tissue protein extraction reagent (T-PER) was obtained 
from Pierce (Rockford, IL). Dual Color Molecular Weight Markers were from Bio-Rad 
(Hercules, CA).  All other chemicals were purchased form Sigma (St. Louis, MO).  
 
Tissue Isolation 
Rats were anesthetized with ketamine-xylazine (4:1) cocktail (50 mg/kg 
intraperitoneal injection) and supplemented as necessary for reflexive response.  
Soleus and extensor digitorum longus (EDL) were rapidly removed, blotted dry, 
weighed, and immediately frozen in liquid nitrogen.  Tissues were stored at -80° C until 
use. 
 
In situ TUNEL Staining 
Cross sections of 8µm thickness were obtained from mid-belly of the soleus and 
EDL muscles using an IEC Minotome Cryostat.  After fixing with 4% paraformaldehyde, 
sections were permeabilized with 0.1% Triton X-100 in 0.1% sodium citrate for 2 min at 
40C. The TUNEL reaction mixture (50µl) containing terminal deoxynucleotidyl 
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transferase (TdT) and fluorescein-dUTP was added to the sections and incubated for 60 
min at 370 C in a dark humidified chamber. After washing with phosphate buffered saline 
(PBS), pH 7.4, tissues were incubated with an anti-dystrophin antibody (1:500) for 30 
min at room temperature, washed, and then incubated with secondary antibody for 30 
min at room temperature.  After rinsing with PBS, sections were mounted and 
counterstained DAPI (4, 6-diamidino-2-phenylindole) to visualize nuclei. Three randomly 
selected regions from each cross-section were visualized with Olympus fluorescence 
microscope (Melville, NY) using a 20X objective. Control experiments performed in 
parallel using DNase 1 or without TdT were used to verify specificity of labeling. Images 
were digitally recorded using a CCD (Olympus, Melville, NY) camera. 
 
Immunoblotting 
EDL and soleus muscles were homogenized on ice, twice for 30 seconds in T-
PER (1 mL/100mg tissue weight) supplemented with 1mM PMSF, 1mM Na3VO4, and 
1mM NaF. After centrifugation (10,000 X g for 15 min at 4ºC), the supernatant was 
separated from the pellet and stored in aliquots at -80ºC until use. Protein 
concentrations were determined in triplicate using the Pierce 660 nm protein assay 
(Pierce, Rockford, IL) with bovine serum albumin (BSA) as the standard. Samples were 
diluted to a concentration of 2.0 mg/ml in SDS-loading buffer, boiled for 5 minutes, and 
40 µg of total protein was separated using SDS-PAGE. Transfer of protein onto 
nitrocellulose membranes was performed using standard conditions [60].  After transfer, 
membranes were blocked in 5% milk in Tris-buffered saline with 0.05% Tween 20 (TBS-
T) for 1h at room temperature and then incubated with the appropriate primary antibody 
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overnight at 40C. After washing with 1X TBS-T, membranes were exposed to 
horseradish peroxidase-labeled IgG secondary antibody for 1h at room temperature. 
Protein bands were visualized with ECL (Amersham Biosciences) and the exposure 
time was adjusted to keep the integrated optical densities (IODs) within a linear and 
non-saturated range.  Band signal intensity was quantified by densitometry using 
Imaging software (Alpha Ease FC) and normalized to GAPDH to verify equal protein 
transfer to membranes.  Molecular weight markers (Bio-rad) were used as molecular 
mass standards and NIH-3T3 cell lysates were included as positive controls.   
 
Data analysis 
Results are presented as mean ± SEM. Differences among age groups were 
evaluated by one way analysis of variance (ANOVA) followed the student-Newman-
Keuls test using Sigma Stat 3.5 statistical program. The level of significance accepted 
for differences was set at P<0.05. 
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Results 
Aging related muscle atrophy is associated with an increase in the number of 
TUNEL positive myonuclei  
Compared to 6-month rats, soleus muscle to body weight ratio was 25% lower in 
both 26-months and 30-months (P<0.05).  Similarly, EDL muscle to body weight ratio 
was 24% and 28% less in the 26- and 30-month animals (P < 0.05). EDL and soleus 
muscle to body weight ratio was unchanged between 26- and 30-months (Table 1, 
Figure 1) 
TUNEL staining was used to detect and quantify apoptosis in the soleus and EDL 
muscles of aging F344BN female rats.  Compared to 6-month old animals, the 
percentage of TUNEL positive nuclei was significantly increased by 28.5 and 62.7-fold 
(P < 0.05) in the 26- and 30-month soleus (Figure 2).  Similarly in the EDL, the number 
of TUNEL positive nuclei was increased by 2.2 fold (P < 0.05) in 30-month animals 
(Figure 2). 
 
The regulation of Bax and Bcl-2 protein expression with aging differs across 
muscle type 
Compared to 6-month animals, the expression of pro-apoptotic Bax was 37% 
and 53% higher (P < 0.05) in the soleus muscles from 26- and 30-month old animals. 
Conversely, the amount of the anti-apoptotic Bcl-2 was 61% and 48% lower (P < 0.05) 
in 26- and 30-month solei compared to that observed in 6-month animals. Aging 
increased the ratio of Bax to Bcl-2 in the soleus by 263% and 206% at 26- and 30-
months, respectively (P < 0.05). 
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In the EDL, Bax expression was 31% higher (P < 0.05) in 30-month old animals 
compared to that found in muscles from 6- and 26-month animals. Unlike the soleus, 
Bcl-2 expression in the EDL was not changed with aging. The ratio of Bax to Bcl-2 in the 
aging EDL was 31% higher at 30-months compared to 6-months (Figure 3). 
 
Age-related changes in caspase and α-fodrin expression are regulated differently 
across muscle type 
Compared to 6-month animals, caspase-3 protein levels were 29% and 61% 
higher (P < 0.05) in 26- and 30-month solei muscles.  Similarly, aging increased the 
amount of caspase-3 in the EDL by 60% (P < 0.05) at 30-months. Contrary to what was 
found in 6-month animals, caspase-9 protein expression was 28% and 36% higher (P < 
0.05) in the 30-month soleus and EDL muscles (Figure 4). Total Caspase-12 expression 
was not changed with aging in either the soleus or EDL muscles (Figure 5). Compared 
to soleus muscles from 6-months animals, the amount of cleaved α-fodrin was 83% 
higher (P < 0.05) at 30-months. Conversely, the amount of alpha-fodrin cleavage in the 
EDL muscle was unchanged with aging (Figure 6).   
 
Muscle type has an influence on the correlation between muscle apoptosis and 
the expression of apoptosis regulatory factors  
The relationships among Bax, Bcl-2, Bax to Bcl-2 ratio, caspase-3, caspase-9, α-
fodrin and percentage of TUNEL positive nuclei were analyzed using the Pearson‟s 
correlation (R2).  In the soleus and EDL muscles, the expression of Bax (soleus: R2 = 
0.75, (P < 0.05); EDL: R2 = 0.21, (P < 0.05 )), Bax to Bcl-2 ratio (soleus: R2 = 0.41, (P < 
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0.05); EDL: R2 = 0.55, (P < 0.05 )), caspase-3 (soleus: R2 = 0.69, (P < 0.05); EDL: R2 = 
0.05, (P < 0.05 )), caspase-9 (soleus: R2 = 0.37, P < 0.05); EDL: R2 = 0.15, (P < 0.05 )) 
and the amount of cleaved α-fodrin (soleus: R2 = 0.49, P< 0.05); EDL: R2 = 0.22, (P < 
0.05 )) were positively correlated with apoptosis (Figures 7, 8).  Conversely, Bcl-2 
expression (soleus: R2 = 0.476, (P< 0.05); EDL: R2 = 0.5, P< 0.05)   was negatively 
correlated with the percentage of TUNEL positive nuclei.   
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Discussion 
To our knowledge, this is the first report to examine the regulation of muscle 
apoptosis between muscle types in an aging female animal. Similar to previous work we 
employed the F344BN rat model because of its increased longevity and decreased 
cumulative lesion incidence compared to other strains [42]. Furthermore, F344BN rats 
display an age-related atrophy that is similar to that observed in humans [43]. 
Consistent to that observed in the aging male F344BN animals, the data of the present 
study demonstrate that the regulation of apoptotic signaling mechanisms may be 
different in fast and slow muscle types.  
 
Age-related apoptotic mechanisms appear to differ in fast- and slow-twitch 
muscles of the female rat 
Previous reports in humans and rats have suggested that the degree and rate of 
muscle atrophy may differ between muscle types and across gender [38,55].  We 
observe a similar finding here. Using animal survivability curves developed by the 
National Institutes on Aging that were based on large, long term studies examining 
F344BN mortality rates we selected animals that corresponded roughly to humans in 
the 3rd, 7th and 8th decade of life [42,43].  This latter time point was chosen because the 
World Health Organization defines this age group as „„elderly‟‟, a time where muscle 
atrophy and dysfunction are present and accelerating in humans [61].  Although 
different in absolute age, it should also be noted that the 6-, 26-, and 30-month female 
animals used in the present study are likely to be of similar “physiological age” to 6-, 30- 
and 36-month male animals given that these age groups occupy similar positions on 
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their respective probability of survival curves [42].  Using these crude measures as a 
means to compare across male and female animals, the findings of the present study 
are consistent with the notion that muscle loss with aging is less in the female than male 
F344BN animal.  For example, previous data has suggested that the degree of muscle 
atrophy continues to increase with age in the male F344BN rat [43]. Conversely, here 
we demonstrate that age-related muscle loss in female animals plateaus at 26-months 
and remains constant thereafter (Figure 1).  Although similar differences between the 
rates of muscle atrophy with aging between genders have been demonstrated in 
humans [38,55] it is clear that muscle atrophy in human females is a progressive 
process that appears to continue even at advanced age. Why the loss of muscle mass 
appears to remain constant after a certain age in the female F344BN is not clear, 
however it is possible that the examination of animals older than 30-months of age 
could have yielded different results. Future studies perhaps employing female animals 
older than the ones used in this study will no doubt be useful in clarifying this possibility.  
Previous data examining the regulation of muscle apoptosis with aging has 
suggested that the degree of apoptosis may vary by muscle type [30,31].  Our findings 
support this contention.  For example, in the aging soleus muscle the amount of TUNEL 
positive nuclei increases sharply at 26-months and then again at 30-months of age 
(Figure 2). Conversely, in the aging female EDL the number of TUNEL positive nuclei 
does not appear to significantly increase until the animals are 30-months of age. In 
addition the incidence of apoptotic nuclei are less in the aging EDL than soleus. This 
latter finding is similar to our previous data when examining the incidence of apoptosis 
in the aging F344BN male. Why the amount of apoptosis might differ between muscle 
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types is not entirely clear. Given that different muscle types exhibit differences in their 
resistance to muscle atrophy, metabolic profile, and degree of usage it would not be 
surprising that that fast- and slow-twitch muscles may also exhibit different proclivities to 
nuclei loss during aging. Additional investigation using other muscles or muscles that 
contain a mixture of fiber types will be useful in expanding our understanding of this 
finding.  
It has been suggested that the mechanisms of age-related apoptosis may differ 
in fast- and slow-twitch muscle types [29,62,63]. The data of the present study are 
consistent with this notion.  Indeed, one of the main findings of the present study is that 
the regulation of apoptotic regulators appears to be at variance between muscle types 
with aging.  For example, Bcl-2 content in the soleus is decreased with aging, whereas 
in the EDL, Bcl-2 content remained constant (Figure 3).  Similarly, in the soleus, Bax 
content was significantly increased at 26- and 30-months, while in the EDL; Bax levels 
did not change until 30-months (Figure 3). Support for this notion is given by our 
analysis of the Bax to Bcl-2 ratio; in the aging EDL the ratio of Bax to Bcl-2 remains 
constant until 30-months of age while in the soleus this ratio is elevated significantly at 
26-months (Figure 3).  Finally, we observed what appears to be a higher degree of 
correlation between Bax and the number of TUNEL positive cells in the soleus than in 
the EDL (Figure 7).  Why the content of apoptotic regulators or the relationship between 
regulators and the extent of apoptosis may differ between muscle types is not entirely 
clear.  Recent data has suggested that enhanced production of reactive oxygen (ROS) 
and nitrogen species (RNS) may induce a pro-apoptotic shift of the pattern of 
expression of Bcl-2 proteins (e.g., increased Bax to Bcl-2 ratio) [64].  Given the fact that 
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the soleus muscle contains a higher concentration of mitochondria and a greater 
reliance on oxidative activity to produce energy than the EDL it is possible that it also 
experiences a higher elevation of age-related ROS. This finding, if present, may help to 
explain the differences we see between the soleus and EDL in the regulation of Bax and 
Bcl-2. Further experimentation to directly evaluate these factors is likely to increase our 
understanding of this possibility.  
Increases in mitochondrial dysfunction with aging is considered a powerful 
stimulus for apoptosis [23].  Impairment of mitochondrial function has been shown to 
trigger the release of cytochrome-c [65].  It is thought that this process is controlled, at 
least in part, by the ratio of Bax to Bcl-2 with the release of cytochrome-c and cell death 
favored as the balance shifts toward Bax [66].  In the aging F344BN female EDL and 
soleus muscles the alterations we observe in the ratio of Bax to Bcl-2 suggest that 
mitochondrial-mediated processes may play a role in regulation of age-related muscle 
apoptosis.  It is postulated that cytosolic cyotochrome-c couples with apoptotic protease 
activating factor-1 (Apaf-1) which results in formation of apoptosome and the cleavage 
of caspase-9.  Caspase-9 activation in turn activates caspase- 3 resulting in proteolytic 
disassembly of the cell [67].  Similar to our findings for Bax and Bcl-2, it appears that the 
the amount of  caspase-3 and its upstream activator caspase-9 with aging (Figure 4) 
and the degree of correlation between caspase-3, -9 levels and the percentage of 
TUNEL positive nuclei may differ between the EDL and soleus (Figure 7). Nonetheless, 
a common theme in both muscles was no significant alteration in the levels of cleaved 
caspase-3 and caspase-9 in both the aging EDL and soleus muscles (data not shown).  
Taken together, these data suggest that there is no activation of caspase with aging in 
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these muscles.  This latter finding is  similar to what we [31] and others have previously 
found regarding the regulation of apoptotic signaling in male F344BN rats [8,29]. 
Nonetheless, these data suggest that the mechanisms of age-related muscle apoptosis 
may differ with gender. To our knowledge, this finding has not been reported before.  
 
Calpain cleavage of α-fodrin is highly correlated with age-related apoptosis in the 
slow-twitch soleus muscle  
Age-related changes in the ability of skeletal muscle to regulate intracellular 
calcium (calcium dyshomeostasis) have been demonstrated and it is thought that this 
phenomenon is capable of causing cellular apoptosis [23]. Increases in cellular calcium, 
if excessive, can result in the activation of calpains. Calpains are a family of calcium-
dependent, non-lysosomal cysteine proteases that can participate in the breakdown of 
numerous proteins and have been postulated to play a role in muscle atrophy [68,69]. 
The α-fodrin protein is a 240 kDa protein that can be cleaved by activated calpains to 
yield a N-terminal fragment of 150 kDa [70,71]. The cleavage of α-fodrin has been 
observed in many types of cell death and the use of immunoblotting to detect calpain-
dependent proteolysis of α-fodrin fragment has proven to be a reliable method to 
demonstrate calpain activation in cell lysates [72,73].  Similar to our findings for Bax and 
Bcl-2, the aged EDL and soleus appear to regulate calpain activation differently with 
aging. For example, we show increased calpain-dependent cleavage of α-fodrin in the 
soleus with aging but not the EDL (Figure 6).  No evidence of capase-dependent 
cleavage of α-fodrin was present in either muscle (data not shown). These data are 
different from what has previously been shown in the aging male F344BN where 
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evidence of caspase-dependent cleavage was evident in both the soleus and EDL [31]. 
The possibility that disparity exists between the two muscle types in the degree of 
calpain activation with aging is also represented by differences in the strength of the 
correlation between the cleavage of α-fodrin and the number of TUNEL positive nuclei 
(Figure 8).  Taken together, these data suggest that proteolytic activities are regulated 
differently between muscle types with aging.  Further, these data also support our 
hypothesis that the mechanism(s) underlying age-related muscle loss may differ 
between fiber types and with gender. Whether other signaling pathways involved in 
regulating muscle atrophy exhibit similar age-related muscle type differences in 
regulation is unknown.  Additional studies examining other possible regulators of 
apoptosis such as apoptosis inducing factor (AIF) or endonuclease G will certainly be 
helpful in furthering our understanding if or how gender may influence the mechanism(s) 
involved in muscle apoptosis.   
 
Conclusion 
 These data suggest caspase-independent apoptosis may play a role in the age-
related loss of muscle nuclei in the skeletal muscles of the female F344BN rat.  In 
addition, we confirm previous observations demonstrating that proteolytic and apoptotic 
regulatory events are regulated differently in fast- and slow-twitch muscles. Further 
research directed against determining the role of other apoptotic signaling pathways as 
a mechanism of age-related muscle nuclei loss is warranted.   
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TABLE AND FIGURE LEGENDS 
 
Table 1: Muscle weight and muscle to body weight ratio in young adult (6-month), aged 
(26-month) and very aged (30-month) female F344BN rats. Values are expressed as 
mean ± SEM, n = 4 per each group. * indicates significant difference from young adult 
(6 month) age group (P < 0.05). 
 
Figure 1: Changes in the muscle to body weight ratio with age in A) Soleus B) EDL of 
female F344BN rats. Values are mean ± SEM, n = 4 per each group. * indicates 
significant difference from young adult (6-month) age group (P < 0.05). 
 
Figure 2:  Quantification of apoptosis with age is shown in A) Soleus B) EDL of female 
F344BN rats.  Apoptotic myonuclei were visualized with TUNEL staining. Muscle 
borders were visualized using mouse monoclonal antibody dystrophin (C-terminus) and 
all nuclei were stained with 4‟, 6-diamidino-2-phenyllindole (DAPI). Arrows highlight 
TUNEL-positive nuclei in the image. Data are presented as mean ± SEM. * indicates 
significant difference from young adult (6-month) age group (P < 0.05). † indicates 
significant difference from aged (26-month) group (P < 0.05). n = 4 per each group. 
 
29 
 
 
Figure 3: Mitochondrial content of pro-apoptotic Bax shown in A) Soleus B) EDL and 
anti-apoptotic Bcl-2 shown in C) Soleus D) EDL of female F344BN rats with age as 
determined by western blot analysis. Expression of Bax and Bcl-2 were normalized for 
GAPDH. Representative Immunoblot images of Bax, Bcl-2 and GAPDH were showed 
for each group in insets. C) Bax to Bcl-2 ratio changes with age in both soleus and EDL 
muscles. Data are presented as mean ± SEM. * indicates significant difference from 
young adult (6-month) age group (P < 0.05). † indicates significant difference from aged 
(26-month) group (P < 0.05). n = 4 per each group. 
 
Figure 4:  Expression of tissue content of caspase-3 shown in A) Soleus B) EDL and 
caspase-9 shown in C) soleus D) EDL of female F344BN rats with age as determined 
by western blot analysis. Expression of caspase-3 and caspase-9 were normalized for 
GAPDH. Representative Immunoblot images of caspase-3, caspase-9 and GAPDH 
were showed for each group. Data are presented as mean ± SEM. * indicates 
significant difference from young adult (6-month) age group (P < 0.05). † indicates 
significant difference from aged (26 month) group (P < 0.05). n = 4 per each group. 
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Figure 5:  Expression of tissue content of cleaved (42 kDa) compared to total (55 kDa) 
caspase-12 with aging in A) soleus and B) EDL muscles of female F344BN rats as 
determined by western blot analysis. GAPDH blots were shown below the figure to 
show equal loading in all lanes along with cleaved (42 kDa) and total (55 kDa) caspase-
12 blots. Data are presented as mean ± SEM. * indicates significant difference from 
young adult (6-month) age group (P < 0.05). † indicates significant difference from aged 
(26-month) group (P < 0.05). n = 4 per each group. 
 
Figure 6:  Expression of cleaved α-fodrin (150 kDa) compared to total α-fodrin (240 
kDa) with aging in A) soleus and B) EDL muscles of female F344BN rats as determined 
by western blot analysis. GAPDH blots were shown below the figure to show equal 
loading in all lanes along with cleaved and total α-fodrin blots. Data are presented as 
mean ± SEM. * indicates significant difference from young adult (6-month) age group (P 
< 0.05). † indicates significant difference from aged (26 month) group (P < 0.05). n = 4 
per each group. 
 
Figure 7: Relationships between TUNEL staining (% of TUNEL positive nuclei) and 
protein expression of Bax, Bcl-2, and Bax to Bcl-2 ratio were investigated in the soleus 
(A, C, E) and EDL (B, D, E) by examining the Pearson product-moment correlation 
coefficient (R2).  
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Figure 8: Relationships between TUNEL staining (% of TUNEL positive nuclei) and 
protein expression of caspase-3, caspase-9, and cleaved to total α-fodrin were 
investigated in the soleus (A, C, E) and EDL (B, D, E) by examining the Pearson 
product-moment correlation coefficient (R2).  
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Table 1 
Age Soleus to EDL to 
groups body wt ratio body wt ratio
6m 228.00±8.7 109.13±7.5 0.48±0.02 115.88±6.6 0.51±0.02
26m 322.25±25.9 116.38±9.2 0.36±0.04 * 124.63±1.1 0.39±0.03 *
30m 310.00±11.5 111.75±2.2 0.36±0.01 * 114.25±11.1 0.37±0.02 *
Soleus (mg) EDL (mg)Body wt (g)
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CHAPTER 4 
 
Conclusions 
 
1. Although we demonstrate an increase in the expression levels of caspase-9 and 
caspase-3 with aging there is no change in the level of active caspases (caspase-3, 
caspase-9 and caspase-12). These data suggests that age-associated muscle 
apoptosis in the female F344XBN may occur in a caspase-independent manner.  
 
2. We confirm previous observations in male rats [31] demonstrating that proteolytic and 
apoptotic regulatory events are regulated differently in fast- and slow-twitch muscles. 
We observe the alterations in the number of apoptotic cells, Bcl-2, and the ratio of 
Bax to Bcl-2 across muscle type. In addition, we also found that the calpain-
dependent cleavage of α-fodrin is highly correlated with age-related apoptosis in the 
slow-twitch soleus. 
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Future Directions 
Future directions for research based on this study should focus on the further 
understanding of molecular mechanisms underlying the sarcopenia in females.  
 
1. We observed that caspase-independent apoptosis may be responsible for age-
related muscle nuclei loss in skeletal muscles of female F344BN rats. To further 
investigate this possibility, it may be useful to examine other upstream molecules 
that may be involved in this pathway like AIF and EndoG. Similarly, the 
examination of other caspase-dependent apoptogenic factors like cytochrome c 
and apaf-1 may lead to a greater understanding of apoptosis may be occurring in 
the aged female F344BN rats. 
 
2. It is well known that Bcl-2 family proteins and mPTP are involved in the 
regulation of mitochondrial membrane stability. Investigating the changes in 
expression of mPTP components and Bcl-2 family proteins other than Bax and 
Bcl-2 over the course of aging process may also reveal new and interesting 
information regarding our understanding of how aging affects skeletal muscle in 
female F344BN rats.  
 
3. The free radical theory of aging suggests that age-related increases in the 
concentration of reactive oxygen species (ROS) may play a role in aging [74]. It 
has been shown that enhanced production of reactive oxygen species (ROS) and 
nitrogen species (RNS) may induce a pro-apoptotic shift in the expression of Bcl-
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2 proteins. To address this possibility, the effects of these ROS with aging in the 
skeletal muscle could be analyzed by oxyblot analysis / or by some 
immunohistochemical methods such as 8-OHdG (8-Hydroxy-2‟-deoxyguanosine) 
staining. Similarly, the effects of RNS with aging in the skeletal muscle could be 
analyzed by dot blot analysis for nitrotyrosine. Additional data regarding how 
aging affects ROS and RNS levels in the skeletal muscles of aging male and 
female F344BN rats will no doubt be useful in increasing our understanding of 
gender differences because of direct estrogen effects of skeletal muscle in 
women. 
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APPENDIX 
 
This section includes western blot film properties reports, raw data tables, and 
statistics of various molecules in soleus and EDL used for this study. 
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Soleus: 
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Raw data:  
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films. 
%C 6 m 26 m 30 m 
1a 8.20 11.14 13.04 
1b 9.10 11.96 13.62 
1c 9.00 12.38 13.78 
2a 7.90 11.24 12.94 
2b 9.00 12.06 13.52 
2c 9.20 12.84 13.46 
    
N 6.00 6.00 6.00 
Mean 8.73 11.94 13.39 
SD 0.54 0.66 0.33 
SEM 0.24 0.29 0.15 
%RE 100.00 136.68 153.34 
SEM 2.78 3.36 1.70 
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Statistics:  
One way analysis of variance (ANOVA) 
Normality Test: Passed (P = 0.112) 
Equal Variance Test: Passed (P = 0.537) 
Group Name N  Missing Mean Std Dev SEM  
6 months 6 0 8.733 0.543 0.222  
26 months 6 0 11.936 0.655 0.267  
30 months 6 0 13.391 0.332 0.135 
Source of Variation  DF   SS   MS    F    P   
Between Groups 2 68.150 34.075 122.582 <0.001  
Residual 15 4.170 0.278    
Total 17 72.319  
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
Power of performed test with alpha = 0.050: 1.000 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method): 
Comparisons for factor:  
Comparison Diff of Means p q P P<0.050  
30 months vs. 6 months 4.658 3 21.641 <0.001 Yes  
30 months vs. 26 months 1.455 2 6.760 <0.001 Yes  
26 months vs. 6 months 3.203 2 14.881 <0.001 Yes  
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Raw data:  
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films 
%C 6 m 26 m 30 m 
1a 18.10 5.86 7.80 
1b 18.40 6.49 8.57 
1c 16.60 8.52 11.24 
2a 17.70 5.96 7.61 
2b 18.80 6.29 8.67 
2c 16.90 8.06 11.45 
    
N 6.00 6.00 6.00 
Mean 17.75 6.86 9.22 
SD 0.86 1.14 1.69 
SEM 0.38 0.51 0.76 
%RE 100.00 38.67 51.97 
SEM 2.17 2.86 4.27 
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Stastics:  
One way ANOVA 
Normality Test: Passed (P = 0.183) 
Equal Variance Test: Passed (P = 0.567) 
Group Name N  Missing Mean Std Dev SEM  
6 months 6 0 17.750 0.860 0.351  
26 months 6 0 6.865 1.136 0.464  
30 months 6 0 9.224 1.693 0.691  
 
Source of Variation  DF   SS   MS    F    P   
Between Groups 2 393.504 196.752 120.568 <0.001  
Residual 15 24.478 1.632    
Total 17 417.982  
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference  (P = <0.001). 
Power of performed test with alpha = 0.050: 1.000 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
Comparisons for factor:  
Comparison Diff of Means p q P P<0.050  
6 months vs. 26 months 10.885 3 20.873 <0.001 Yes  
6 months vs. 30 months 8.526 2 16.348 <0.001 Yes  
30 months vs. 26 months   2.360       2     4.524    0.006      Yes  
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Raw data:  
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films 
%C 6 m 26 m 30 m 
1a 9.70 12.58 16.95 
1b 10.70 14.51 15.83 
1c 8.40 10.19 13.45 
2a 9.50 12.58 17.09 
2b 11.00 14.39 15.72 
2c 8.30 9.97 13.66 
    
N 6.00 6.00 6.00 
Mean 9.60 12.37 15.45 
SD 1.12 1.96 1.57 
SEM 0.50 0.88 0.70 
%RE 100.00 128.87 160.94 
SEM 5.24 9.15 7.34 
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Stastics:  
One way ANOVA 
Normality Test: Passed (P = 0.415) 
Equal Variance Test: Passed (P = 0.568) 
Group Name  N  Missing Mean Std Dev SEM  
6 months 6 0 9.600 1.124 0.459  
26 months 6 0 12.372 1.963 0.801  
30 months 6 0 15.450 1.575 0.643  
 
Source of Variation DF   SS   MS    F    P   
Between Groups 2 102.777 51.389 20.289 <0.001  
Residual 15 37.993 2.533    
Total 17 140.770 
  
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference  (P = <0.001). 
Power of performed test with alpha = 0.050: 1.000 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
Comparisons for factor:  
Comparison Diff of Means p q P P<0.050  
30 months vs. 6 months 5.850 3 9.004 <0.001 Yes  
30 months vs. 26 months 3.079 2 4.739 0.005 Yes  
26 months vs. 6 months 2.772        2   4.266     0.009     Yes  
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Raw data:  
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films. 
%C 6 m 26 m 30 m 
1a 9.00 16.58 17.67 
1b 12.70 13.42 13.16 
1c 10.90 10.31 14.16 
2a 9.40 15.54 17.29 
2b 12.80 13.42 13.06 
2c 11.20 10.31 14.48 
    
N 6.00 6.00 6.00 
Mean 11.00 13.27 14.97 
SD 1.60 2.60 2.02 
SEM 0.71 1.16 0.91 
%RE 100.00 120.59 136.07 
SEM 6.49 10.55 8.23 
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Statistics:  
One way ANOVA 
Normality Test: Passed (P = 0.543) 
Equal Variance Test: Passed (P = 0.658) 
Group Name  N  Missing Mean Std Dev SEM  
6 months 6 0 11.000 1.596 0.652  
26 months 6 0 13.265 2.595 1.059  
30 months 6 0 14.968 2.025 0.827  
 
Source of Variation DF   SS   MS    F    P   
Between Groups 2 47.543 23.772 5.329 0.018  
Residual 15 66.915 4.461    
Total 17 114.458  
 
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = 0.018). 
Power of performed test with alpha = 0.050: 0.659 
All Pair wise Multiple Comparison Procedures (Student-Newman-Keuls Method) : 
Comparisons for factor:  
Comparison Diff of Means p q P P<0.050  
30 months vs. 6 months 3.968 3 4.601 0.014 Yes  
30 months vs. 26 months 1.702 2 1.974 0.183 No  
26 months vs. 6 months 2.265 2 2.627 0.083 No  
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Raw data:  
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films 
 
Total caspase-12:       
%C 6 m 26 m 30 m 
1a 1.00 0.67 1.40 
1b 1.00 0.71 1.06 
1c 1.00 0.76 0.82 
2a 1.00 0.73 1.41 
2b 1.00 0.71 1.58 
2c 1.00 0.75 0.81 
 
Cleaved caspase-12 
%C 6 m 26 m 30 m 
1a 1.00 1.04 1.03 
1b 1.00 0.92 0.85 
1c 1.00 0.89 0.73 
2a 1.00 1.06 1.10 
2b 1.00 0.89 0.69 
2c 1.00 0.89 0.72 
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Cleaved to total caspase-12 ratio 
%C 6 m 26 m 30 m 
1a 1.00 1.55 0.73 
1b 1.00 1.30 0.81 
1c 1.00 1.18 0.89 
2a 1.00 1.45 0.78 
2b 1.00 1.26 0.43 
2c 1.00 1.18 0.90 
    
N 6.00 6.00 6.00 
Mean 1.00 1.32 0.76 
SD 0.00 0.15 0.17 
SEM 0.00 0.07 0.08 
%RE 100.00 132.24 75.83 
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Statistics: 
One way ANOVA 
Normality Test: Failed (P < 0.050) 
Test execution ended by user request, ANOVA on Ranks begun 
Kruskal-Wallis One Way Analysis of Variance on RanksTuesday, July 07, 2009, 
11:34:44 PM 
Data source: Data 1 in Notebook 7 
Group N  Missing  Median    25%      75%     
6months 6 0 1.000 1.000 1.000  
26months6 0 1.283 1.185 1.452  
30months6 0 0.795 0.734 0.895  
H = 15.726 with 2 degrees of freedom.  (P = <0.001) 
The differences in the median values among the treatment groups are greater than 
would be expected by chance; there is a statistically significant difference (P = <0.001) 
To isolate the group or groups that differ from the others use a multiple comparison 
procedure. 
All Pairwise Multiple Comparison Procedures (Tukey Test): 
Comparison Diff of Ranks q P<0.05   
26months vs 30months 72.000 5.506 Yes   
26months vs 6months  36.000 2.753 No   
6months  vs 30months 36.000 2.753 No  
Note: The multiple comparisons on ranks do not include an adjustment for ties. 
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Raw data:  
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films 
Total α-fodrin: 
%C 6 m 26 m 30 m 
1a 1.00 1.10 0.95 
1b 1.00 1.18 1.10 
1c 1.00 1.40 0.99 
2a 1.00 1.03 1.16 
2b 1.00 1.12 1.03 
2c 1.00 1.45 1.00 
 
Cleaved α-fodrin:  
%C 6 m 26 m 30 m 
1a 1.00 1.41 2.45 
1b 1.00 1.35 1.67 
1c 1.00 1.34 1.37 
2a 1.00 1.40 2.63 
2b 1.00 1.48 1.85 
2c 1.00 1.42 1.46 
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Cleaved to total α-fodrin ratio: 
%C 6 m 26 m 30 m 
1a 1.00 1.28 2.58 
1b 1.00 1.14 1.52 
1c 1.00 0.95 1.39 
2a 1.00 1.36 2.27 
2b 1.00 1.32 1.79 
2c 1.00 0.98 1.46 
    
N 6.00 6.00 6.00 
Mean 1.00 1.17 1.83 
SD 0.00 0.17 0.49 
SEM 0.00 0.08 0.22 
%RE 100.00 117.24 183.44 
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Statistics: 
One way ANOVA 
Normality Test: Failed (P < 0.050) 
Test execution ended by user request, ANOVA on Ranks begun 
Kruskal-Wallis One Way Analysis of Variance on Ranks Tuesday, July 07, 2009, 
11:52:21 PM 
Data source: Data 1 in Notebook 3 
Group N  Missing  Median    25%      75%     
6months 6 0 1.000 1.000 1.000  
26months6 0 1.210 0.983 1.319  
30months6 0 1.656 1.461 2.266 
H = 12.231 with 2 degrees of freedom.  (P = 0.002) 
The differences in the median values among the treatment groups are greater than 
would be expected by chance; there is a statistically significant difference (P = 0.002) 
To isolate the group or groups that differ from the others use a multiple comparison 
procedure. 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method): 
Comparison Diff of Ranks q P<0.05   
30months vs 6months  60.000 4.588 Yes   
30months vs 26months 48.000 5.435 Yes   
26months vs 6months  12.000 1.359 No  
Note: The multiple comparisons on ranks do not include an adjustment for ties. 
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EDL: 
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Raw data:  
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films 
%C 6 m 26 m 30 m 
1a 8.80 9.51 12.25 
1b 9.40 11.05 12.60 
1c 10.70 10.10 12.91 
2a 8.70 9.89 12.71 
2b 10.00 11.15 12.31 
2c 10.20 9.70 12.72 
    
N 6.00 6.00 6.00 
Mean 9.63 10.23 12.58 
SD 0.80 0.70 0.26 
SEM 0.36 0.31 0.11 
%RE 100.00 106.23 130.63 
SEM 3.72 3.25 1.19 
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Statistics: 
One way ANOVA 
Normality Test: Passed (P = 0.849) 
Equal Variance Test: Passed (P = 0.083) 
Group Name  N  Missing Mean Std Dev SEM  
6 months  6 0 9.633  0.802  0.327  
26 months  6 0 10.233  0.700  0.286  
30 months  6 0 12.584  0.257  0.105  
Source of Variation DF   SS   MS    F    P   
Between Groups 2 29.193 14.596 36.524 <0.001  
Residual 15 5.995 0.400    
Total 17 35.187  
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = <0.001). 
Power of performed test with alpha = 0.050: 1.000 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method): 
Comparisons for factor:  
Comparison Diff of Means p q P P<0.050  
30 months vs. 6 months 2.951 3 11.435 <0.001 Yes  
30 months vs. 26 months 2.351 2 9.110 <0.001 Yes  
26 months vs. 6 months 0.600 2 2.325 0.121 No 
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Raw data:  
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films 
%C 6 m 26 m 30 m 
1a 10.70 10.17 9.86 
1b 11.40 11.25 11.53 
1c 13.40 10.50 8.99 
2a 10.40 10.17 9.95 
2b 11.40 11.45 11.63 
2c 13.20 10.60 9.18 
    
N 6.00 6.00 6.00 
Mean 11.75 10.69 10.19 
SD 1.26 0.54 1.14 
SEM 0.57 0.24 0.51 
%RE 100.00 90.98 86.73 
SEM 4.81 2.07 4.34 
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Statistics: 
One way ANOVA 
Normality Test: Passed (P = 0.051) 
Equal Variance Test: Passed (P = 0.401) 
Group Name  N  Missing Mean  Std Dev SEM  
6 months  6 0  11.750 1.265  0.516  
26 months  6 0  10.691 0.544  0.222  
30 months  6 0  10.190 1.141  0.466  
Source of Variation  DF   SS      MS        F     P   
Between Groups    2 7.609     3.805    3.571 0.054  
Residual    15 15.983   1.066    
Total     17 23.592 
The differences in the mean values among the treatment groups are not great enough 
to exclude the possibility that the difference is due to random sampling variability; there 
is not a statistically significant difference  (P = 0.054). 
Power of performed test with alpha = 0.050: 0.426 
The power of the performed test (0.426) is below the desired power of 0.800. 
Less than desired power indicates you are less likely to detect a difference when one 
actually exists. Negative results should be interpreted cautiously. 
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Raw data:  
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films 
%C 6 m 26 m 30 m 
1a 7.90 6.88 13.19 
1b 7.90 14.00 14.41 
1c 10.30 10.27 13.54 
2a 7.70 6.97 12.98 
2b 7.40 14.29 14.61 
2c 10.40 10.37 13.84 
    
N 6.00 6.00 6.00 
Mean 8.60 10.46 13.76 
SD 1.37 3.23 0.65 
SEM 0.61 1.44 0.29 
%RE 100.00 121.67 160.00 
SEM 7.11 16.79 3.39 
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Statistics: 
One way ANOVA 
Normality Test: Passed (P = 0.187) 
Equal Variance Test: Passed (P = 0.052) 
Group Name  N  Missing Mean Std Dev SEM  
6 months 6 0 8.600 1.368 0.559  
26 months 6 0 10.464 3.229 1.318  
30 months 6 0 13.760 0.652 0.266  
Source of Variation DF   SS   MS    F    P   
Between Groups 2 81.933 40.966 9.658 0.002  
Residual 15 63.627 4.242    
Total 17 145.560  
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = 0.002). 
Power of performed test with alpha = 0.050: 0.937 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method): 
Comparisons for factor:  
Comparison Diff of Means p q P P<0.050  
30 months vs. 6 months 5.160 3 6.137   0.002 Yes  
30 months vs. 26 months 3.297 2 3.921 0.014 Yes  
26 months vs. 6 months 1.864         2    2.216   0.138     No  
 
 
79 
 
 
 
 
80 
 
 
Raw data:  
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films 
%C 6 m 26 m 30 m 
1a 9.40 11.25 13.43 
1b 9.60 11.29 12.22 
1c 8.70 8.11 9.59 
2a 9.60 11.25 13.43 
2b 9.20 11.09 12.31 
2c 8.60 8.43 9.51 
    
N 6.00 6.00 6.00 
Mean 9.18 10.23 11.75 
SD 0.44 1.53 1.78 
SEM 0.20 0.68 0.80 
%RE 100.00 111.45 127.91 
SEM 2.14 7.44 8.68 
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Statistics: 
One way ANOVA 
Normality Test: Passed (P = 0.155) 
Equal Variance Test: Passed (P = 0.326) 
Group Name  N  Missing Mean  Std Dev SEM  
6 months  6 0 9.183  0.440  0.180  
26 months  6 0        10.235  1.528  0.624  
30 months  6 0   11.747  1.783  0.728  
Source of Variation DF   SS   MS    F    P   
Between Groups 2 19.927 9.964 5.238 0.019  
Residual 15 28.534 1.902    
Total 17 48.461  
The differences in the mean values among the treatment groups are greater than would 
be expected by chance; there is a statistically significant difference (P = 0.019). 
Power of performed test with alpha = 0.050: 0.649 
All Pairwise Multiple Comparison Procedures (Student-Newman-Keuls Method): 
Comparisons for factor:  
Comparison Diff of Means p q P P<0.050  
30 months vs. 6 months 2.564 3 4.553 0.015 Yes  
30 months vs. 26 months 1.512 2 2.685 0.077 No  
26 months vs. 6 months 1.051 2 1.867 0.207 No 
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Raw data:  
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films 
Total caspase-12 
%C 6 m 26 m 30 m 
1a 1.00 1.21 1.19 
1b 1.00 1.08 1.05 
1c 1.00 1.00 0.90 
2a 1.00 1.23 1.21 
2b 1.00 1.09 1.06 
2c 1.00 1.00 0.90 
 
Cleaved caspase-12: 
%C 6 m 26 m 30 m 
1a 1.00 1.06 0.89 
1b 1.00 1.03 0.81 
1c 1.00 1.19 1.19 
2a 1.00 1.02 0.87 
2b 1.00 1.06 0.77 
2c 1.00 1.20 1.20 
 
 
Cleaved to total caspase-12: 
%C 6 m 26 m 30 m 
84 
 
 
1a 1.00 0.87 0.75 
1b 1.00 0.95 0.77 
1c 1.00 1.19 1.32 
2a 1.00 0.83 0.72 
2b 1.00 0.97 0.73 
2c 1.00 1.20 1.33 
    
N 6.00 6.00 6.00 
Mean 1.00 1.00 0.94 
SD 0.00 0.16 0.30 
SEM 0.00 0.07 0.14 
%RE 100.00 100.30 93.57 
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Statistics: 
One way ANOVA 
Normality Test: Failed (P < 0.050) 
Test execution ended by user request, ANOVA on Ranks begun 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
Group  N  Missing  Median    25%      75%     
6months   6 0 1.000 1.000 1.000  
26months  6 0 0.961 0.874 1.193  
30months  6 0 0.758 0.728 1.324  
H = 1.747 with 2 degrees of freedom.  (P = 0.417) 
The differences in the median values among the treatment groups are not great enough 
to exclude the possibility that the difference is due to random sampling variability; there 
is not a statistically significant difference    (P = 0.417) 
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Raw data:  
This section represents the raw data tables produced from spot densitometry of the 
immunoblot films 
Total α-fodrin: 
%C 6 m 26 m 30 m 
1a 1.00 0.93 0.84 
1b 1.00 0.93 0.83 
1c 1.00 1.07 1.02 
2a 1.00 0.93 0.83 
2b 1.00 0.92 0.82 
2c 1.00 1.05 1.02 
 
Cleaved α-fodrin: 
%C 6 m 26 m 30 m 
1a 1.00 1.08 1.25 
1b 1.00 0.84 0.89 
1c 1.00 0.92 0.97 
2a 1.00 1.03 1.19 
2b 1.00 0.83 0.86 
2c 1.00 0.87 0.97 
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Cleaved to total α-fodrin ratio: 
%C 6 m 26 m 30 m 
1a 1.00 1.15 1.49 
1b 1.00 0.90 1.07 
1c 1.00 0.85 0.95 
2a 1.00 1.11 1.43 
2b 1.00 0.90 1.05 
2c 1.00 0.84 0.96 
    
N 6.00 6.00 6.00 
Mean 1.00 0.96 1.16 
SD 0.00 0.14 0.24 
SEM 0.00 0.06 0.11 
%RE 100.00 95.84 115.81 
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Statistics: 
One way ANOVA 
Normality Test: Failed (P < 0.050) 
Test execution ended by user request, ANOVA on Ranks begun 
Kruskal-Wallis One Way Analysis of Variance on Ranks  
Data source:  
Group N  Missing  Median    25%      75%     
6 months 6 0  1.000  1.000  1.000  
26 months 6 0  0.900   0.855  1.109  
30 months 6 0  1.061   0.956  1.429  
H = 3.106 with 2 degrees of freedom.  (P = 0.212) 
The differences in the median values among the treatment groups are not great enough 
to exclude the possibility that the difference is due to random sampling variability; there 
is not a statistically significant difference    (P = 0.212) 
